Paul Burton - 16 Jun 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Medical Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
16 Jun 2022
Net transactions value
$0
Form type
4
Filing time
21 Jun 2022, 16:03:31 UTC
Previous filing
03 Mar 2022
Next filing
09 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Award $0 +6,902 $0.000000 6,902 16 Jun 2022 Common Stock 6,902 $121.08 Direct F1
transaction MRNA Restricted Stock Units Award $0 +3,663 $0.000000 3,663 16 Jun 2022 Common Stock 3,663 $0.000000 Direct F2
transaction MRNA Stock Option (Right to Buy) Award $0 +19,772 $0.000000 19,772 16 Jun 2022 Common Stock 19,772 $121.08 Direct F3
transaction MRNA Restricted Stock Units Award $0 +10,990 $0.000000 10,990 16 Jun 2022 Common Stock 10,990 $0.000000 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option will vest and become exercisable on June 16, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F2 25% of the shares subject to this restricted stock unit award will vest on June 16, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F3 50% of this option will vest and become exercisable on June 16, 2025 and the remaining 50% will vest and become exercisable on June 16, 2026, subject to the recipient's continued service.
F4 50% of the shares subject to this restricted stock unit award will vest on June 16, 2025 and the remaining 50% will vest on June 16, 2026, subject to the recipient's continued service.